With bold growth, Fox Rothschild brings together 1,000 attorneys coast to coast. We offer the reach and resources of a national law firm combined with the personal touch and connections of a boutique firm.
Our Mission
Solving problems is our top priority. We invest the time to get to know you and understand your needs. We work hard to win every client’s loyalty. We do that by providing creative solutions and excellent client service.
By Memorandum Opinion entered by The Honorable Sue L. Robinson in Amgen Inc. v. Sanofi, et al., Civil Action No. 14-317-SLR (D.Del., October 20, 2015), the Court rendered its Markman Opinion construing six (6) disputed terms in U.S. Patent Nos. 8,829,165("the '165 patent"), 8,859,741 ("the '741 patent"), and 8,871,914 ("the '914 patent").
within Immigration and Corporate/Commercial Law topic(s)
with Finance and Tax Executives
with readers working within the Automotive, Basic Industries and Healthcare industries
By Memorandum Opinion entered by The Honorable Sue L. Robinson
in Amgen Inc. v. Sanofi, et al., Civil Action No.
14-317-SLR (D.Del., October 20, 2015), the Court rendered its
Markman Opinion construing six (6) disputed terms in U.S.
Patent Nos. 8,829,165("the '165 patent"), 8,859,741
("the '741 patent"), and 8,871,914 ("the
'914 patent").
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
